• We have published our new research paper to prove the efficiency of our MACE SELEX Technology for the selection of highly specific DNA Aptamer for small molecules target. (Dec 02, 2022)
• LinkBIO and Nara Medical University have signed a “Joint Research and Development Agreement for the Treatment of Blood Diseases”. (July 25, 2022)
• Joint research collaboration between LinkBIO and HitGen to improve drug discovery screening platform for small molecules. (June 01, 2022)
• We are pleased to announce that Nikkei Biotechnology has published the latest article on MACE® Tech for Aptamer Screening which includes commentary from our CTO Professor Keitaro Yoshimoto. (May 13, 2022)
• Funakoshi has published a new article about LinkBIO MACE® Technology for Aptamers Separation and how it could accelerate both Therapeutics and Diagnostics Discovery P5~7). (March 1, 2022)
• We are happy to announce that we successfully got our MACE® Trademark Registration (Trademark Registration No. 6515690)- (February 18, 2022)
• We are pleased to announce the Grant of Japan Patent No. 6994198 for “Methods for screening nucleic acid aptamers”. (December 15, 2021)
• Strategic Alliance Agreement with Funakoshi (December 1, 2021)
• Announcement of collaborative research contract with Maruho Co., Ltd. (October 13, 2021)
• Academic paper related MACE® was accepted (Sep. 22, 2021)
• Patent registration in China (Sep. 21, 2021)
• Appointment of new advisor (Sep. 01, 2021)
• Receipt of subsidies (July. 15, 2021)
• Patent registration in Taiwan (Jun 21, 2021)• Patent registration in USA (Apr. 13, 2021)
• Appointment of new director (Mar. 06, 2021)